Dialectic Therapeutics Receives $14.4 Million Texas Company Product Development Research Award from the Cancer Prevention & Research Institute of Texas prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Dialectic Therapeutics Receives FDA Clearance of IND Application for Lead Antiapoptotic Protein Targeted Degradation (APTaD) Candidate DT2216
News provided by
Share this article
DALLAS, March 3, 2021 /PRNewswire/ Dialectic Therapeutics, Inc. (Dialectic
®), a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel
Antiapoptotic
Targeted
Degradation (APTaD™) technology. In pre-clinical studies supported through a Seed Award from the Cancer Prevention & Research Institute of Texas (CPRIT), DT2216 selectively induces cancer cells to degrade B-cell lymphoma extra-large, or BCL-XL, stimulating the cells to commit suicide or become more susceptible to chemotherapy.